Project Grant R01AI194523

Award Date 8/1/25
Completion Date 7/31/30
Dollars Obligated $710K
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
This $147,656 federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to understand the role of transmembrane proteins in the cell division process of the malaria parasite Plasmodium falciparum. The award, effective January 22, 2025 through October 31, 2027, will enable the integration of biochemical and super-resolution microscopy approaches to decipher...
The Scripps Research Institute was awarded a $779,915 Project Grant by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The 5-year grant, effective May 5, 2025, will support research to investigate the chromatin remodeling functions of polyphosphate condensates in the opportunistic pathogen Pseudomonas aeruginosa. The project aims to define the relationship between polyphosphate, a stress-responsive...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $223,176 to The Trustees of the University of Pennsylvania to investigate the molecular architecture and ultrastructural features of the Cryptosporidium host-parasite interface. The research aims to uncover the three-dimensional structure, composition, and function of key interface components like secreted...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $812,603 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to the University of Houston System. The grant aims to develop selective calcium-dependent protein kinase 1 (CDPK1) inhibitors that can efficiently access the gastrointestinal system to treat cryptosporidiosis, a significant public health threat with limited treatment options. The research will focus on structure-activity...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $556,375 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the J. Craig Venter Institute, Inc. (JCVI) on July 23, 2025. The grant, titled "Identifying the Molecular Determinants of Thermoadaptation and Parasitic Growth of Histoplasma capsulatum", aims to sequence and assemble approximately 150 new clinical isolates of the fungal pathogen Histoplasma capsulatum. The goal is to identify...
This $153,056 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) to The Washington University will support research to investigate heme homeostasis mechanisms in the malaria parasite Plasmodium falciparum. The research aims to identify parasite heme-binding proteins and assess their essentiality for parasite viability, as well as investigate the role of the heme detoxification protein PfHDP in parasite...
This $531,245 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will fund research by Yale University to structurally and functionally characterize the sorting platform component of the type III secretion system (T3SS) in Salmonella bacteria. Through a multidisciplinary approach involving bacterial genetics, biochemistry, microscopy, and cryo-electron microscopy, the research aims to...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $910,905.00 to the Scripps Research Institute to advance HIV vaccine development using a lipid nanodisc platform. The key objectives are to: Solve the structures of engineered transmembrane HIV envelope (Env) proteins incorporated into lipid nanodiscs in complex with broadly neutralizing antibodies targeting the...
This Project Grant award, totaling $902,964.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The grant supports research to evaluate mechanisms that restrain or enhance alveolar macrophage (AM) responses to Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis, with the goal of understanding the regulation of early events during MTB infection. The key...
This Project Grant award of $1,180,755, provided by the National Science Foundation (NSF) under the Biological Sciences (CFDA 47.074) federal grant program, supports research to investigate the evolutionary transition of host-microbe interactions from commensal symbionts to blood parasites. The research will use a combination of microscopy and genomics to compare the invasion machinery between related virulent pathogens and mutualistic members of Apicomplexa, which includes the parasites that...

This Project Grant award of $709,891.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research on the structure and mechanism of the polar tube invasion apparatus from microsporidian parasites. The key objectives are to: 1) study the architecture of the polar tube in its post-fired state and capture intermediates of the firing process, including cargo transport, using cryo-electron tomography; 2) biochemically and structurally characterize the individual protein components of the polar tube organelle using X-ray crystallography, single particle cryo electron microscopy, and protein-protein interaction assays; and 3) define the mechanism of host cell invasion by the polar tube using live-cell optical microscopy. The research is being conducted by The Johns Hopkins University, a leading private, non-profit research institution, from August 1, 2025 to July 31, 2030. This work aims to provide fundamental insights into the unique invasion process of microsporidian parasites, which are emerging pathogens classified as NIAID Category B opportunistic pathogens that can cause microsporidiosis in immunocompromised patients.

Generated 8/5/25, 2:47 AM